MARLBOROUGH,
Mass., June 21,
2017 /PRNewswire/ -- RXi Pharmaceuticals
Corporation (NASDAQ: RXII), a clinical-stage RNAi company
developing innovative therapeutics that address significant unmet
medical needs, announced today the completion of enrollment in its
Phase 1/2 study RXI-109-1501. This multi-center, multi-dose,
dose escalation trial is being conducted in patients with advanced
neovascular or 'wet' age-related macular degeneration (AMD) where
retinal scarring can result in continued vision loss. RXI-109 is a
self-delivering RNAi (sd-rxRNA®) compound developed to target
connective tissue growth factor (CTGF), a key regulator of scar
formation.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"We are very pleased with the progress of this clinical
trial and happy to report that RXI-109 has been well tolerated with
no drug related issues occurring to date," said Dr. Gerrit Dispersyn, Chief Development Officer of
RXi Pharmaceuticals. He continued, "The completion of
enrollment is an important study milestone as this means that we
are likely to finish patient follow-up before year end, as planned
and previously communicated."
The primary endpoint for RXI-109-1501 is to evaluate the
safety and tolerability of RXI-109, but in the study other
endpoints are included to assess RXI-109's potential for clinical
activity using numerous assessments to monitor ocular
health and visual acuity. In this Phase 1/2
study, each subject receives a total of four doses of
RXI-109 at one month intervals. RXI-109 is administered by
intravitreal injection in one eye only. The dosing period (3
months) is followed by a four month observation period. Several
dose levels are evaluated in a small number of subjects in this
first trial in order to establish safety information and to help
determine the dosing regimen for continued study.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the pioneering
discovery of RNAi, scientists at RXi have harnessed the naturally
occurring RNAi process which can "silence" or down-regulate the
expression of a specific gene that may be overexpressed in a
disease condition. RXi developed a robust RNAi therapeutic platform
including self-delivering RNA (sd-rxRNA) compounds that selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include cell-based immunotherapy, dermatology, and ophthalmology.
RXi's extensive patent portfolio provides for multiple product and
business development opportunities across a broad spectrum of
therapeutic areas and we actively pursue research collaborations,
partnering and out-licensing opportunities with academia and
pharmaceutical companies. Additional information may be found on
the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to,
statements about: our ability to successfully develop RXI-109,
Samcyprone™ and our other product candidates (collectively "our
product candidates"); the future success of our clinical trials
with our product candidates; the timing for the commencement and
completion of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and to not
act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-announces-completion-of-enrollment-of-phase-12-clinical-trial-with-rxi-109-for-retinal-scarring-300477263.html
SOURCE RXi Pharmaceuticals Corporation